top of page

TUESDAY, june 16  10:00AM ET

Leveraging proprietary neurodegenerative disease platform and growing body of compelling data to advance the first potential approved treatment for Huntington’s disease
Maurice Zauderer, Ph.D.
President and Chief Executive Officer

Maurice Zauderer, Ph.D. has served as our President and Chief Executive Officer and a member of our board of directors since our inception in April 2001. Prior to founding the company, Dr. Zauderer was an Associate Professor at the University of Rochester and has also held senior faculty positions at Columbia University. During his academic career, Dr. Zauderer held the position of visiting scientist at the Laboratory of Cell Biology, the Ontario Cancer Institute and the National Cancer Institute. Dr. Zauderer received a B.S. in Physics from Yeshiva University and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.

Vaccinex, Inc. (Nasdaq: VCNX) is a publicly traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.

Asset 1.png
Asset 2.png
Asset 3.png
Moderated by:
Jenene Thomas, CEO, JTC Team
© 2020 Virtual Investor  All rights reserved.
Fireside_Masthead3DAYS_Artboard 2.png
Asset 1.png
bottom of page